Ballentine Partners, LLC Unity Biotechnology, Inc. Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding UBX
# of Institutions
1Shares Held
4.41MCall Options Held
0Put Options Held
0About Unity Biotechnology, Inc.
- Ticker UBX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,036,200
- Market Cap $13.5M
- Description
- Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...